Citi's $35bn Booking Blunder Exposes Banking's Control Gap
2026년 11월 22일 게시
기사 읽기
안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
Let’s be honest, who among us hasn’t stared at a blister pack of pills and thought, there must be a better way? The daily ritual of remembering medication is a universal chore. Forgetting a vitamin is one thing, but for millions managing chronic conditions, a missed dose can have serious consequences. It’s a colossal, expensive problem, and frankly, it’s a bit archaic. I think the pharmaceutical industry has finally woken up to this, and its solution might just be a shot in the arm for investors.
The core issue here isn’t the medicine itself, it’s us. We are forgetful, busy, and inconsistent creatures. Studies show that up to half of all patients with long term conditions don't take their medication as prescribed. This isn't just a minor inconvenience, it leads to poorer health outcomes and costs healthcare systems, like our beloved NHS, an absolute fortune. For years, the industry’s answer was, well, to just make more pills.
Now, a much cleverer approach is gaining serious momentum. Instead of a daily pill, imagine a single injection every month, or even every few months. This whole shift is what some are calling the Injectable Drug Revolution: What's Next Beyond Pills?, and it’s about time. We’re seeing real proof of concept, too. GlaxoSmithKline recently got its long acting HIV prevention jab approved for NHS reimbursement. To me, that’s a massive signal that the powers that be are willing to pay a premium not just for a drug, but for the convenience and compliance that comes with it.
So, who should investors be watching in this space? GSK is clearly a frontrunner. Having navigated the regulatory maze with its HIV treatment, it has a clear head start and a pipeline that suggests this is a long term strategy, not a one off punt. They’ve proven the commercial model works.
Then you have firms like Vertex Pharmaceuticals. They’ve made their name tackling complex rare diseases, which requires some seriously sophisticated science. Their expertise in advanced drug delivery makes them a fascinating player. They might not be the most obvious name in injectables right now, but they have the brains and the technical clout to make a significant impact if they choose to pivot more aggressively in this direction.
And let’s not forget the specialists. A company like Alkermes has built its entire business around this concept, particularly for treating mental health and addiction. These are areas where ensuring a patient stays on their medication is notoriously difficult, giving Alkermes a unique and valuable niche. They’ve been quietly perfecting this technology whilst the giants were focused elsewhere.
The investment case seems rather compelling. These long acting formulations are complex to develop and manufacture, which creates a natural barrier to entry for cheap generic competition. This could mean longer, more profitable patent lives. Furthermore, healthcare providers are desperate for solutions that improve patient outcomes and reduce long term costs, so they may be willing to pay higher prices for these advanced treatments.
Of course, it’s not all smooth sailing. These drugs are expensive to develop, and not every medication can be successfully converted into a long release formula. There’s also the human element. Whilst many might jump at the chance to ditch daily pills, others have a genuine fear of needles. Manufacturing these complex medicines at scale is another significant hurdle. Still, looking at the broader trends in healthcare, from telemedicine to personalised medicine, this move towards less frequent, more manageable treatments feels less like a fad and more like the future.
전체 바스켓 보기:Injectable Drug Revolution: What's Next Beyond Pills?
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
2026년 11월 22일 게시
기사 읽기
2026년 11월 22일 게시
기사 읽기
2026년 11월 21일 게시
기사 읽기
2026년 11월 21일 게시
기사 읽기
2026년 11월 19일 게시
기사 읽기